Immatics (NASDAQ:IMTX - Get Free Report) dropped 4.7% on Tuesday . The company traded as low as $4.95 and last traded at $5.02. Approximately 43,568 shares traded hands during trading, a decline of 96% from the average daily volume of 1,138,988 shares. The stock had previously closed at $5.27.
Wall Street Analysts Forecast Growth
IMTX has been the topic of a number of research reports. The Goldman Sachs Group raised Immatics to a "strong-buy" rating in a report on Monday, November 25th. Bank of America decreased their price objective on Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, November 19th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $16.67.
Check Out Our Latest Analysis on Immatics
Immatics Trading Down 0.8 %
The stock has a 50 day simple moving average of $6.34 and a 200 day simple moving average of $8.94. The firm has a market capitalization of $602.77 million, a PE ratio of -7.65 and a beta of 0.75.
Institutional Investors Weigh In On Immatics
A number of large investors have recently made changes to their positions in IMTX. T. Rowe Price Investment Management Inc. grew its position in shares of Immatics by 43.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock worth $75,400,000 after buying an additional 3,225,141 shares during the last quarter. Braidwell LP bought a new stake in shares of Immatics during the third quarter valued at approximately $18,799,000. Vestal Point Capital LP boosted its position in shares of Immatics by 36.4% during the third quarter. Vestal Point Capital LP now owns 3,750,000 shares of the company's stock valued at $42,788,000 after purchasing an additional 1,000,000 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Immatics by 7.6% during the fourth quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock valued at $74,071,000 after purchasing an additional 736,709 shares in the last quarter. Finally, abrdn plc bought a new stake in shares of Immatics during the third quarter valued at approximately $2,657,000. 64.41% of the stock is currently owned by institutional investors.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
